I'm LongbridgeAI, I can summarize articles.The Week
Cameco (CCJ) fell 18% this week, closing Friday at $58 after ending the prior Friday at $70.73. The move was almost one-way: Monday opened at $69.05 and closed at $65.99, then Tuesday, Wednesday and Thursday each printed lower closes, with Friday sinking to a low of $57.87 before settling at $58. The weekly range was 17.16%, and the stock carved out fresh 52-week lows on multiple days.
Key Events
Two threads ran through this week’s news. First, technical signals soured, with a MACD death cross flagged on Monday and several put options jumping as much as 400% on the same day the stock shed nearly 7%. Second, the market kept chewing over Cameco’s $1 billion at-the-market share sale plan and the loss it recently reported, a topic that appeared repeatedly in English coverage. The stock marked new 52-week lows on Tuesday, Thursday and Friday as the narrative played out.
Analyst Ratings
Among 21 institutions covering the name, 12 rate it buy, 7 rate it overweight and 2 rate it hold, with no sell or underweight ratings. The consensus recommendation is buy, and the consensus target price sits around $115.91, about 99.85% above the current $58 price. Targets run from a low of $82.21 to a high of $169.02, a wide spread. Within the coal and consumable fuels industry, Cameco ranks 2nd out of 16 covered stocks.
The Week Ahead
The macro calendar is heavy on Tuesday, with US FHFA house prices, the Case Shiller 20-city home price indices, consumer confidence and the Richmond Fed composite index all due. On the company side, the next earnings report is not until 12 February 2027 for Q4 FY2026, so there is no near-term catalyst from financials. Investors will watch how macro data feeds market sentiment and whether uranium prices and the broader sector stabilise.
In Short
This week’s story was a one-way slide with repeated 52-week lows, driven less by company-specific bad news than by deteriorating technicals and unease around the share sale plan. The analyst picture is split in an interesting way: the consensus remains buy, and the consensus target sits nearly double the current price, yet the target range is extremely wide, suggesting institutions disagree sharply on valuation. The key question going forward is whether uranium prices find a floor and how quickly the market absorbs the dilution.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
